A practical reference on Synaptogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
In 1999, the Institute of Medicine published the Safety of Silicone Breast Implants (1999) study that reported no evidence that saline-filled and silicone-gel filled breast implant devices caused systemic health problems; that their use posed no new health or safety risks; and that local complications are "the primary safety issue with silicone breast implants", in distinguishing among routine and local medical complications and systemic health concerns." In 2000, the FDA approved saline breast implant Premarket Approval Applications (PMA) containing the type and rate data of the local medical complications experienced by the breast surgery patients. "Despite complications experienced by some women, the majority of those women still in the Inamed Corporation and Mentor Corporation studies, after three years, reported being satisfied with their implants." The premarket approvals were granted for breast augmentation, for women at least 18 years old, and for women requiring breast reconstruction. In 2006, for the Inamed Corporation and for the Mentor Corporation, the U.S. Food and Drug Administration lifted its restrictions against using silicone-gel breast implants for breast reconstruction and for augmentation mammoplasty. Yet, the approval was conditional upon accepting FDA monitoring, the completion of 10-year-mark studies of the women who already had the breast implants, and the completion of a second, 10-year-mark study of the safety of the breast implants in 40,000 other women.
=== Applications in biochemistry === Spectrophotometry is an important technique used in many biochemical experiments that involve DNA, RNA, and protein isolation, enzyme kinetics and biochemical analyses. Since samples in these applications are not readily available in large quantities, they are especially suited to be analyzed in this non-destructive technique. In addition, precious sample can be saved by utilizing a micro-volume platform where as little as 1uL of sample is required for complete analyses. A brief explanation of the procedure of spectrophotometry includes comparing the absorbency of a blank sample that does not contain a colored compound to a sample that contains a colored compound. This coloring can be accomplished by either a dye such as Coomassie Brilliant Blue G-250 dye measured at 595 nm or by an enzymatic reaction as seen between β-galactosidase and ONPG (turns sample yellow) measured at 420 nm. The spectrophotometer is used to measure colored compounds in the visible region of light (between 350 nm and 800 nm), thus it can be used to find more information about the substance being studied. In biochemical experiments, a chemical and/or physical property is chosen and the procedure that is used is specific to that property to derive more information about the sample, such as the quantity, purity, enzyme activity, etc.
While neurotherapy is a relatively young medical treatment in conventional Western biomedicine (that relies on a scientific approach and evidence-based practice), different age-old cultural practices of traditional Indian, Egyptian, and Chinese medicine have been using neuromodulation elements thousands of years ago. Long before humans discovered the science of electricity, ancient physicians used electric currents to treat various physical and mental conditions, including epilepsy, vertigo, and depression. In the ancient world, nature fulfilled many roles now served by technology, including providing sources of electricity. Before electricity was formally understood, people utilized electric fish to deliver therapeutic shocks. The Egyptians knew of the Nile catfish (Malapterurus electricus), capable of producing electric shocks. A depiction of this fish, dating back to 2750 BC, is found in a mural in the tomb of the architect Ti at Saqqara, Egypt. Egyptians weren't the only Mediterranean culture to feature the catfish in their art; similar murals appeared in the Roman city of Pompeii some 3,000 years later, though 1,000 miles to the north. While these murals don't confirm whether the fish were used medically, ancient Egyptian writings on papyri from 4,700 years ago document their use in pain relief. Later historians like Pliny and Plutarch also noted that Egyptians employed electric eels to treat joint pain, migraines, depression, and epilepsy.
Under Rama's lead, the PS formed the Alliance for a European Albania, which united several political parties. The alliance won the 2013 Albanian parliamentary election, thus returning the Socialists to the government after 8 years. The Socialist Party, now running alone, again won the 2017 election and the 2021 election, winning 74 seats in both of them and is thus currently able to rule Albania alone, although it is externally supported by the Social Democratic Party in parliament.
In fish and other wildlife, selenium is necessary for life but toxic in high doses. For salmon, the optimal selenium concentration is about 1 microgram selenium per gram of whole body weight. Much below that level, young salmon die from deficiency; much above, they die from toxic excess.
Sources: en.wikipedia.org
== History == Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. As of 2015, setipiprant is currently under development by Allergan for the prevention of androgenic alopecia after their successful acquisition of Kythera.
==== Singapore ==== Chick-fil-A opened a pop-up restaurant at Esplanade Mall for three days from June 26 through 28, 2024, being the first Asian country to host a Chick-fil-A pop-up. On October 17, 2024, Chick-fil-A officially announced it would be opening in Singapore in late 2025, making the first Asian country to open the brand, and would be investing US$75 million into its first restaurant in the country for 10 years. The restaurant opened on December 11, 2025.
=== Postclassical Europe === Pepper was so valuable that it was often used as collateral or even currency. The taste for pepper (or the appreciation of its monetary value) was passed on to those who would see Rome fall. Alaric, king of the Visigoths, included 3,000 pounds of pepper as part of the ransom he demanded from Rome when he besieged the city in the fifth century. After the fall of Rome, others took over the middle legs of the spice trade, first the Persians and then the Arabs; Innes Miller cites the account of Cosmas Indicopleustes, who travelled east to India, as proof that "pepper was still being exported from India in the sixth century". By the end of the Early Middle Ages, the central portions of the spice trade were firmly under Islamic control. Once into the Mediterranean, the trade was largely monopolised by Italian powers, especially Venice and Genoa. The rise of these city-states was funded in large part by the spice trade. A riddle authored by Saint Aldhelm, a seventh-century Bishop of Sherborne, sheds some light on black pepper's role in England at that time:
The doctor who had ordered the tests was a diabetes expert who specialised in insulin and hypoglycaemic episodes, and she had believed the incident to be suspicious. No doctor or medical staff member had prescribed her this drug, and she had no condition that required it to be issued. The amount of insulin in Hall's blood was about 12 times the normal level, and it had been injected into her system. The insulin was manufactured and not produced naturally in the body. It had been injected into her abdomen, as indicated by the fact that a bulge was found under her skin there that was consistent with a large injection of fluid. Doctors believed it was done by someone with nursing or medical experience. The results of the tests led the hospital to contact the police. It was discovered after Hall's death that insulin had also been taken from the storage fridge, and Norris later admitted that he was the last person to have accessed this fridge before Hall had been injected with insulin. Two vials of insulin were found to have been taken from the fridge, which had to have been taken by someone during the night shift which Norris was working when Hall became unwell. Norris had on a previous occasion been caught stealing drugs from the hospital. Norris also admitted that he was the last person to see Hall at 4.30 am, half an hour before she fell into the hypoglycaemic coma. at around 5 am.
Phenylacetic acid was added to switch it to producing the highly potent penicillin G. This strain could produce up to 550 milligrams of penicillin per litre. Pfizer was a small New York company that specialised in making citric acid, for which it had developed deep submergence techniques. This involved converting molasses to citric acid by fermenting it in a large tank in which it was stirred and the pH was carefully controlled. Pfizer's vice president, John L. Smith, whose daughter had died from an infection, put all of Pfizer's resources into the development of a practical deep submergence technique. The company invested $2.98 million in penicillin in 1943 and 1944 (equivalent to $55 million in 2025). Pfizer scientists Jasper H. Kane, G. M. Shull, E. M. Weber, A. C. Finlay and E. J. Ratajak worked on the fermentation process while R. Pasternak, W. J. Smith, V. Bogert and P. Regna developed extraction techniques.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.